• Explore /
  • Poster
  • / Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Arpit Rao

Arpit Rao

Division of Hematology & Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX

Arpit Rao , Glenn Heller , Charles J. Ryan , David James VanderWeele , Lionel D Lewis , Alan Tan , Colleen Watt , Ronald C. Chen , Manish Kohli , Pedro C. Barata , Benjamin Adam Gartrell , Robert Grubb , Amylou C. Dueck , Yujia Wen , Michael J. Morris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04455750

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS194)

DOI

10.1200/JCO.2022.40.6_suppl.TPS194

Abstract #

TPS194

Poster Bd #

P8

Abstract Disclosures

Similar Posters

First Author: Arpit Rao

First Author: Arpit Rao

First Author: Guillaume Grisay

First Author: Alicia K. Morgans